Facebook
Twitter
LinkedIn
ForwardFundamentals in Urology Bundle (2018)
The Fundamentals in Urology course is designed to apply basic science knowledge and principles in development of treatment algorithms. NEW this year, the course has been redesigned to 3 days to allow for less time out of the office and in a convenient location for traveling out of state! This course will provide attendees with valuable skills in developing a rational methodological approach to application of knowledge which will contribute to positive outcomes for patients. New topics for this year include Reflux, Obstruction, and Undescended Testes- Causes and Clinical Implications and Medical and Surgical Management of ED. Attendees will discover the importance of the study of basic sciences and how it transfers into the lifelong learning process and medical practice. This course is designed to ensure a fundamental knowledge of the "why" behind a broad expanse of general urologic conditions. A thorough knowledge of the basic science behind the treatments will allow for better counseling and education of patients by all clinical urologic practitioners.
Target Audience
- Urology Residents
- Allied Health Professionals
Learning Objectives
After attending this course, participants will be able to:
Nephrolithiasis and Infections
- Recognize the basic pathophysiology of nephrolithiasis.
- Identify the indications and options for the medical evaluation of recurrent and first time stone formers.
- Establish an effective algorithm for the medical management of nephrolithiasis.
- Distinguish the appropriate timing of diagnostic methods for treatment of bacteria and fungi in the urinary tract.
Incontinence, Ethics, Obstruction, and Pelvic Pain
- Recall the pathophysiology of pelvic organ prolapse and stress incontinence.
- Describe how to treat pelvic organ prolapse and stress incontinence conditions.
- Review foundational concepts of bioethics.
- Define the meaning of “profession”.
- Discuss key aspects of consent, capacity, research and ethics.
- Identify how to apply consent, capacity, research and ethics to the practice of urology.
- Recognize the role of prophylacitic antibiotics and lower urinary tract imaging for prenatal urinary tract dilation.
- Define the true incidence of IC/BPS and CP/CPPS in the US population.
- Recall what is currently believed about the pathophysiology of chronic pelvic pain.
- Recognize how to use the AUA guidelines to develop a treatment plan for patients with IC/BPS and CP/CPPS.
- Describe current research in pelvic pain and possible new treatment options.
Minimally Invasive Surgery, BPH, Outcomes and Pediatrics
- Identify the physics underlying laser energy, complications occurring due to pneumoperitoneum, and optimizing delivery of shock wave energy.
- Define the medical therapies designed to address benign enlargement of the prostate.
- Explain the basic development of the lower and upper urinary tract including the bladder, kidney and ureters.
- Identify clinical situations that may be encountered if aberrant development occurs in any of the above organ systems.
- Recognize the validity of randomized clinical trials.
- Recognize how to apply the results of outcomes research to clinical practice.
Imaging and Prostate Cancer
- Describe the history of M1 Prostate cancer therapies.
- Identify basics in ADT management.
- Discuss basic science and clinical outcomes of new therapies.
- Identify the appropriate indications for MRI and the basic MRI sequences used in urinary tract imaging.
- Distinguish benign from malignant renal masses.
- Recognize how an MRI of the prostate and urethra can be useful and the key features of prostate tumor on MRI.
Adrenal and Renal Physiology, Bowel Diversions, and Bladder Cancer
- Describe how fundamentals of adrenal anatomy and physiology integrate into the care of the urologic patient.
- Discuss renal physiology for the urologist, especially for the following pathologic states: TUR syndrome, upper urinary tract obstruction, post-obstructive diuresis, pregnancy, renovascular hypertension, and juxtaglomerular tumor.
- Review the major genetic alterations that are present in bladder cancers.
- Define “intrinsic subtypes”.
- Discuss their implications for disease heterogeneity and precision medicine
- Review current understanding of immunotherapy for treatment of bladder cancer.
- Explain rationale for choosing a urinary diversion based on the metabolic derangements associated with each segment of bowel.
Male Infertility, Disorders of Differentiation, and Kidney Cancer
- Explain male reproductive anatomy and physiology.
- Discuss a basic clinical overview of male reproductive medicine and surgery.
- Describe the current clinical and surgical management of all types of localized as well as advanced kidney cancer.
PSA and the Prostate, Neurogenic Bladder, and Reproductive Biology
- Review the current data on the controversies, clinical trials and laboratory testing for prostate cancer screening in asymptomatic men.
- Explain lower urinate tract neurobiology and how disease processes, such as neurologic disease; result in predictable lower urinary tract dysfunction.
- Describe penile anatomy and the physiology of erection.
- Describe the major causes of erectile dysfunction.
- Identify the basic classification, diagnosis and treatment of female sexual dysfunction.
Friday, June 8, 2018
7:00 – 7:30 am Continental Breakfast and Registration
7:30 – 7:45 am Housekeeping Notes
Session 1: Stones, Urodynamics and Inflammation
7:45 – 9:15 am Nephrolithiasis: Physiology, Metabolic Work‐up and Treatment of Stones
Glenn Preminger, MD
9:15 – 9:30 am Break
9:30 – 10:30 am Urodynamics
Mikel Gray, PhD
10:30 – 11:30 am Interstitial Cystitis and Disorders of Pelvic Pain
Robert J. Evans, MD, FACS
11:30 am – 12:30 pm Lunch & Learn with the Experts (Others on Own)
Session 2: Pediatrics
12:30 ‐ 1:30 pm Embryology, Congenital Anomalies, and Disorders of Sexual Differentiation
Patricio C. Gargollo, MD
1:30 – 2:30 pm Reflux, Obstruction, and Undescended Testes – Causes and Clinical Implications
Shukla Aseem, MD
2:30 – 2:45pm Break
Session 3: Urologic Imaging and Infections
2:45 – 4:00 pm MRI for Urologists
Nabeel Sarwani, MD
4:00 – 5:15 pm Urologic Infections: Etiology, Patterns and Pathophysiology
Michel A. Pontari, MD
5:15 – 5:30 pm Course Evaluation
Saturday, June 9, 2018
7:00 – 7:45 am Continental Breakfast
7:30‐ 7:45 am Housekeeping Notes
Session 4: BPH and Science of Minimally Invasive Surgery
7:45 – 8:45 am BPH: Pathophysiology, Drugs, and Trials
Richard K. Lee, MD
8:45 – 9:45 am Lasers, Laparoscopes, and Lithotripters: The Science of Minimally Invasive Urology
Jay D. Raman, MD, FACS
9:45 – 10:00 am Break
Session 5: Infertility and Erectile Dysfunction
10:00 – 11:00 am Infertility and Reproductive Biology in Women and Men
Cigdem Tanrikut, MD
11:00 am – 12:00 pm Medical and Surgical Management of ED
John Mulhall, MD
12:00 – 12:45 pm Lunch & Learn with the Experts (Others on Own)
12:45- 1:00 pm AUA Update
Victor Nitti, MD
Session 6: Prostate Cancer
1:00‐ 2:00 pm PSA, Urine Markers and the Science of Cancer Screening
Leonard G. Gomella, MD, FACS
2:00 – 3:00 pm Management of Advanced Prostate Cancer: Drugs, Mechanisms, Disease, Epidemiology and Molecular Mechanisms
Michael B. Williams, MD
3:00 – 3:15 pm Break
Session 7: Bladder Neurobiology and Pelvic Organ Prolapse
3:15 – 4:15 pm Lower Urinary Tract Neurobiology and Functional Bladder Disorders
Gary Lemack, MD
4:15 – 5:15 pm Pelvic Organ Prolapse and SUI: Mechanisms and Mechanics
Victor Nitti, MD
5:15 – 5:30 pm Course Evaluation
6:00‐ 7:00 pm Saturday Night Social
Sunday, June 10, 2018
7:00 – 7:30 am Continental Breakfast and Registration
7:30 – 7:45 am Housekeeping Notes
Session 8: Bladder Cancer and Bowel Diversions
7:45 – 8:45 am Basic Science of Bladder Cancer
Trinity J. Bivalacqua, MD
8:45 – 9:45 am Bowel Diversions: Physiology Underlying Electrolyte Abnormalities
Tracey Krupski, MD, MPH
9:45‐ 10:00 am Break
Session 9: Adrenal Disorders and Kidney Cancer
10:00 – 11:00 am Adrenal Physiology
Alexander Kutikov, MD, FACS
11:00am – 12:30 pm Molecular Genetics and Principles of Molecular Therapeutics of Kidney Cancer
W. Marston Linehan, MD
12:30 – 12:45pm Course Evaluation and Meeting Adjourn
Travel
Doubletree by Hilton Hotel
237 South Broad Street
Philadelphia, PA 19107
215-983-1600
Website
To hold a reservation, a major credit card number must be provided.
Reference the American Urological Association when making your reservation to receive the special group rate.
To hold a reservation, a major credit card number must be provided. $169 single/double occupancy. Reference the American Urological Association Fundamentals in Urology Course when making your reservation to receive the special group rate.
Cut-off Date
Monday, May 8, 2018. Once the AUA group block is full, which may be prior to the cut-off date, the AUA is unable to guarantee rooms at this rate or at this hotel.
Check-in: 3 p.m.
Check-out: 11 a.m.
Parking
Self-parking: $30.00 per day (overnight)
Valet: $44.00 per day (overnight)
Transportation
Car Rental
Hertz is pleased to offer special discounted car rental rates to AUA course and meeting attendees. Make your car rental reservation online or call 1-800-654-2240 and mention the AUA discount code, CV# 04SG0005.
Know Before You Go
Tourism
The DoubleTree by Hilton Hotel Philadelphia Center City enjoys an ideal location in the heart of Philadelphia's theater district on the Avenue of the Arts. Philadelphia's business district, nightlife and main attractions are minutes from the hotel.
Take in all the sights and sounds of Broad Street such as the Academy of Music across from the hotel, the Kimmel Center for the Performing Arts and Merriam Theater. Choose from a range of restaurants on Walnut Street's 'Restaurant Row' a block away. Visit the Philadelphia Museum of Art with more than 300,000 works of art. Enjoy sporting events at the Philadelphia Sports Complex, home of the Eagles, Phillies, Flyers and Sixers, located two miles away. The city has much to offer every guest!
| Faculty Disclosures: | |||
| Name | Company | Role | Financial |
| Trinity J. Bivalacqua, MD | photocure | Meeting Participant or Lecturer,Scientific Study or Trial | No |
| taris | Scientific Study or Trial | No | |
| taris | Scientific Study or Trial | No | |
| FKD | Scientific Study or Trial | No | |
| Genetech | Scientific Study or Trial | No | |
| Robert J. Evans, MD | allergan | Scientific Study or Trial | Yes |
| urigen | Investment Interest | Yes | |
| allergan | Scientific Study or Trial | Yes | |
| TARIS | Scientific Study or Trial | Yes | |
| aquinox | Consultant or Advisor,Scientific Study or Trial | Yes | |
| Patricio C. Gargollo, MD | Intuitive Surgical | Meeting Participant or Lecturer | Yes |
| Leonard G. Gomella, MD | Astellas | Consultant or Advisor | Yes |
| Janssen | Consultant or Advisor | Yes | |
| Wolters Kluwer | Health Publishing | Yes | |
| McGraw Hill | Health Publishing | Yes | |
| Merck Manual | Health Publishing | Yes | |
| Canadian Journal of Urology | Health Publishing | Yes | |
| MDx Health | Consultant or Advisor | Yes | |
| Merck Pharmaceuticals | Consultant or Advisor | Yes | |
| Bayer | Consultant or Advisor | Yes | |
| Mikel L. Gray, Ph.D. | Laborie Medical | Scientific Study or Trial | Yes |
| 3M Inc | Consultant or Advisor | Yes | |
| Tracey Krupski, MD | Argos | Scientific Study or Trial | No |
| FKD - Instilidrin | Scientific Study or Trial | No | |
| American Cancer Society | Scientific Study or Trial | Yes | |
| NIH | Scientific Study or Trial | No | |
| Alexander Kutikov, MD | UrologyMatch.com LLC | Leadership Position | Yes |
| Visible Health, Inc | Leadership Position | Yes | |
| Richard K. Lee, MD | |||
| Gary E. Lemack, MD | Allergan | Consultant or Advisor,Meeting Participant or Lecturer | Yes |
| Roivant | Consultant or Advisor | Yes | |
| Avadel | Consultant or Advisor | Yes | |
| W. Marston Linehan, MD | |||
| John P. Mulhall, MD | Association of Peyronie's Disease Advocates (APDA) | Leadership Position | No |
| Victor W. Nitti, MD | Astellas | Health Publishing,Scientific Study or Trial | No |
| Allergan | Health Publishing,Scientific Study or Trial | No | |
| Serenity Pharmeuticals | Investment Interest | Yes | |
| Medtronic | Scientific Study or Trial | No | |
| Michel A. Pontari, MD | Lilly | Consultant or Advisor | Yes |
| aquinox | Consultant or Advisor,Scientific Study or Trial | Yes | |
| Glenn M. Preminger, MD | Boston Scientific | Consultant or Advisor | Yes |
| UpToDate | Health Publishing | Yes | |
| Retrophin | Consultant or Advisor,Meeting Participant or Lecturer | Yes | |
| Jay D. Raman, MD | American Kidney Stone Management | Investment Interest | Yes |
| MDx Health | Scientific Study or Trial | No | |
| Nabeel Sarwani, MD | |||
| Aseem R. Shukla, MD | |||
| Cigdem Tanrikut, MD | New England Cryogenic Center | Other | Yes |
| Fertility Research and Practice | Health Publishing | No | |
| Michael B. Williams, M.D. | Astellas | Scientific Study or Trial | No |
| Jannsen | Scientific Study or Trial | No | |
| Pacific Edge Diagnostics | Consultant or Advisor | Yes | |
| Online Educational Modules and Optional Course Faculty: | |||
| Name | Company | Role | Financial |
| Mikel L. Gray, Ph.D. | Laborie Medical | Meeting Participant or Lecturer | Yes |
| 3M Inc. | Consultant or Advisor | Yes | |
| C.D. Anthony Herndon, MD, FAAP, FACS | Nothing to disclose. | ||
| Gladell Paner, MD | Amirsys, Inc. | Health Publishing | Yes |
| Charles D. Scales Jr., MD | NIH/National Institute on Aging | Scientific Study or Trial | Yes |
| Society of Urology Chairpersons and Program Directors | Scientific Study or Trial | Yes | |
| Filament Biosolutions | Scientific Study or Trial | No | |
| NIH/ National Institute of Diabetics and Digestive and Kidney Diseases | Scientific Study or Trial | No | |
| Gilead | Consultant or Advisor | Yes | |
| Astra-Zeneca | Scientific Study or Trial | Yes | |
| Eric A. Singer, MD | Nothing to disclose. | ||
| Necole M Streeper, M.D. | Nothing to disclose. | ||
| Education Council Disclosures: | |||
| Name | Company | Role | Financial |
| Michael R. Abern, MD | Department of Defense Prostate Cancer Research Program | Scientific Study or Trial | Yes |
| American Urological Association Office of Education | Consultant or Advisor | Yes | |
| Department of Defense Prostate Cancer Research Program | Consultant or Advisor | Yes | |
| Sero Andonian, MD | Lumenis | Meeting Participant or Lecturer, Scientific Study or Trial | Yes |
| Timothy Charles Brand, MD | Nothing to disclose | ||
| Anthony A. Caldamone, MD | Nothing to disclose | ||
| Matthew S. Christman, MD | Nothing to disclose | ||
| John D. Denstedt, MD | Cook Urology | Owner, Product Development | Yes |
| Endourological Society | Leadership Position | Yes | |
| Endourological Society | Health Publishing | Yes | |
| Jody Donaldson | Nothing to disclose | ||
| Shelby Englert | Nothing to disclose | ||
| Allen Gao, MD, PhD | Pandomedx | Leadership Position, Owner, Product Development | Yes |
| Matthew Thomas Gettman, MD | COVR Medical | Consultant or Advisor | Yes |
| Intuitive Surgical | Consultant or Advisor | Yes | |
| Exact Sciences | Scientific Study or Trial | Yes | |
| Howard B. Goldman, MD | allergan | Consultant or Advisor | Yes |
| Medtronic | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | Yes | |
| Cook | Scientific Study or Trial | No | |
| Nuvectra | Consultant or Advisor | Yes | |
| Axonics | Consultant or Advisor | Yes | |
| NewUro | Consultant or Advisor | Yes | |
| Galvani | Consultant or Advisor | Yes | |
| bioness | Scientific Study or Trial | No | |
| William C. Huang, MD | Photocure | Scientific Study or Trial | Yes |
| Karl Storz | Scientific Study or Trial | Yes | |
| Intuitive | Meeting Participant or Lecturer | Yes | |
| William C. Hulbert, Jr., MD | Nothing to disclose | ||
| Brant Inman, MD, MS, FRCSC | Dendreon | Scientific Study or Trial | No |
| Genentech Inc | Scientific Study or Trial | No | |
| Combat Medical | Consultant or Advisor, Scientific Study or Trial | Yes | |
| FKD Therapies | Scientific Study or Trial | No | |
| Nucleix | Scientific Study or Trial | Yes | |
| Urogen | Scientific Study or Trial | Yes | |
| Mark L. Jordan MD,FACS | Nothing to disclose | ||
| Martin A. Koyle, MD | Nothing to disclose | ||
| Yair Lotan, MD | abbott | Scientific Study or Trial | No |
| Cepheid | Consultant or Advisor, Scientific Study or Trial | No | |
| Pacific Edge | Scientific Study or Trial | No | |
| FKD | Scientific Study or Trial | No | |
| MDxHealth | Consultant or Advisor, Scientific Study or Trial | Yes | |
| biocancell | Scientific Study or Trial | No | |
| GenomeDx Biosciences Inc | Scientific Study or Trial | No | |
| photocure | Consultant or Advisor, Scientific Study or Trial | No | |
| Nicole Lara Miller, MD | Boston Scientific Corporation | Consultant or Advisor, Meeting Participant or Lecturer | Yes |
| Practical Reviews In Urology | Health Publishing | Yes | |
| Manoj Monga, MD, FACS | Fortec | Other | Yes |
| Ajay Kumar Nangia, MBBS, FACS | AUA News | Leadership Position, Health Publishing | Yes |
| NIH CCN Trial | Scientific Study or Trial | Yes | |
| Urology Care Foundation | Leadership Position | No | |
| AUA Health Policy Council | Leadership Position | No | |
| South Central AUA | Leadership Position | No | |
| ASRM | Leadership Position | No | |
| Curtis Nickel, MD | Farr Laboratories | Consultant or Advisor | Yes |
| Aquinox | Scientific Study or Trial | No | |
| PureTech Health | Consultant or Advisor | Yes | |
| AUA | Health Publishing | Yes | |
| NIH | Scientific Study or Trial | Yes | |
| Canadian Institute of Health Research | Scientific Study or Trial | Yes | |
| Interface Biologics | Consultant or Advisor | Yes | |
| Alvio Therapeutics | Consultant or Advisor | Yes | |
| Seikagaku Corporation | Consultant or Advisor | Yes | |
| Medifocus | Consultant or Advisor | Yes | |
| RedLeaf Medical | Consultant or Advisor | Yes | |
| Victor William Nitti, MD | Astellas | Health Publishing, Scientific Study or Trial | No |
| Allergan | Health Publishing, Scientific Study or Trial | No | |
| Serenity Pharmeuticals | Investment Interest | Yes | |
| Medtronic | Scientific Study or Trial | No | |
| Christopher Porter, MD | Nothing to disclose | ||
| Ganesh V. Raj, MD, PhD | Ptares | Owner, Product Development | Yes |
| C-diagnostics corp | Consultant or Advisor, Investment Interest | Yes | |
| amgen | Meeting Participant or Lecturer | Yes | |
| Johnson and Johnson | Consultant or Advisor, Owner, Product Development | Yes | |
| Astellas | Meeting Participant or Lecturer | Yes | |
| ASTELLAS | Consultant or Advisor, Meeting Participant or Lecturer | Yes | |
| Janssen | Owner, Product Development | Yes | |
| BAYER | Consultant or Advisor, Meeting Participant or Lecturer | Yes | |
| SANOFI | Consultant or Advisor, Meeting Participant or Lecturer | Yes | |
| GaudiumRx | Leadership Position, Investment Interest, Owner, Product Development | Yes | |
| Medivation | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | Yes | |
| EtiraRx | Leadership Position, Investment Interest, Owner, Product Development | Yes | |
| Jay D. Raman, MD | American Kidney Stone Management | Investment Interest | Yes |
| MDx Health | Scientific Study or Trial | No | |
| Lee Richstone, MD | Nothing to disclose | ||
| Heather Schultz | SUNA | Meeting Participant or Lecturer | Yes |
| SUNA | Leadership Position | No | |
| Karl-Dietrich Sievert, MD, PhD | Medtronics | Meeting Participant or Lecturer, Scientific Study or Trial | Yes |
| Allergen | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | Yes | |
| Neotract | Meeting Participant or Lecturer | Yes | |
| Stimguard | Meeting Participant or Lecturer, Scientific Study or Trial | Yes | |
| Joseph A. Smith Jr., MD | Nothing to disclose | ||
| Ryan Patrick Terlecki, MD, FACS | American Medical Systems | Consultant or Advisor, Other | Yes |
| Boston Scientific | Consultant or Advisor | Yes | |
| MicroGen Dx | Consultant or Advisor | Yes | |
| U.S. Department of Defense | Scientific Study or Trial | Yes | |
| Edouard John Trabulsi, MD, FACS | GenomeDx | Consultant or Advisor | Yes |
| Janssen | Consultant or Advisor, Meeting Participant or Lecturer | Yes | |
| Pfizer | Consultant or Advisor, Meeting Participant or Lecturer | Yes | |
| Merck | Meeting Participant or Lecturer | Yes | |
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this live activity and enduring material for a maximum of 33.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Available Credit
- 33.50 AMA PRA Category 1 Credit™
- 33.50 Non-Physician Participation